{
    "clinical_study": {
        "@rank": "62249", 
        "arm_group": [
            {
                "arm_group_label": "NGM282 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 1"
            }, 
            {
                "arm_group_label": "NGM282 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 2"
            }, 
            {
                "arm_group_label": "NGM282 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 3"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, and activity of extended\n      treatment with NGM282 in patients with Primary Biliary Cirrhosis."
        }, 
        "brief_title": "Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Biliary Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis, Biliary", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of NGM 13-0103\n\n          -  Males or females, between 18 and 75 years of age, inclusive\n\n          -  PBC Diagnosis consistent with AASLD and EASL guidelines\n\n          -  Stable dose of UDCA\n\n        Exclusion Criteria:\n\n          -  Chronic liver disease of a non-PBC etiology\n\n          -  Evidence of clinically significant hepatic decompensation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135536", 
            "org_study_id": "14-0104"
        }, 
        "intervention": {
            "arm_group_label": [
                "NGM282 Dose 1", 
                "NGM282 Dose 2", 
                "NGM282 Dose 3"
            ], 
            "description": "NGM282", 
            "intervention_name": "NGM282", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "url": "http://ngmbio.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 602"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "NGM Clinical Study Site 614"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "NGM Clinical Study Site 607"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103", 
        "overall_contact": {
            "email": "melliott@ngmbio.com", 
            "last_name": "Michael A Elliott", 
            "phone": "650-243-5571"
        }, 
        "overall_official": {
            "affiliation": "NGM Biopharmaceuticals, Inc", 
            "last_name": "Stephen J Rossi, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absolute change in plasma ALP from Baseline to Week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage change in bilirubin, ALT, AST, and GGT from Baseline to Week 12 and Week 24", 
            "safety_issue": "No", 
            "time_frame": "12 weeks and 24 weeks"
        }, 
        "source": "NGM Biopharmaceuticals, Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "NGM Biopharmaceuticals Australia Pty Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "NGM Biopharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}